ES2187276A1 - Composiciones orales para el tratamiento de humanos obesos y no diabeticos. - Google Patents

Composiciones orales para el tratamiento de humanos obesos y no diabeticos.

Info

Publication number
ES2187276A1
ES2187276A1 ES200101200A ES200101200A ES2187276A1 ES 2187276 A1 ES2187276 A1 ES 2187276A1 ES 200101200 A ES200101200 A ES 200101200A ES 200101200 A ES200101200 A ES 200101200A ES 2187276 A1 ES2187276 A1 ES 2187276A1
Authority
ES
Spain
Prior art keywords
obesity
including humans
obese
mammals
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200101200A
Other languages
English (en)
Other versions
ES2187276B1 (es
Inventor
De Barbara Ramon Gomis
Carles Marc Claret
Cirera Joan Josep Guinovart
Alvarez Josefa Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Hispania SL
Original Assignee
Quimica Farmaceutica Bayer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200101200A priority Critical patent/ES2187276B1/es
Application filed by Quimica Farmaceutica Bayer SA filed Critical Quimica Farmaceutica Bayer SA
Priority to ES02732763T priority patent/ES2275873T3/es
Priority to DK02732763T priority patent/DK1400246T3/da
Priority to CA002447141A priority patent/CA2447141A1/en
Priority to EP02732763A priority patent/EP1400246B1/en
Priority to BR0210975-1A priority patent/BR0210975A/pt
Priority to US10/477,807 priority patent/US7122209B2/en
Priority to DE60215812T priority patent/DE60215812T2/de
Priority to PT02732763T priority patent/PT1400246E/pt
Priority to PCT/ES2002/000231 priority patent/WO2002098435A1/es
Priority to AT02732763T priority patent/ATE344042T1/de
Publication of ES2187276A1 publication Critical patent/ES2187276A1/es
Application granted granted Critical
Publication of ES2187276B1 publication Critical patent/ES2187276B1/es
Priority to CY20071100138T priority patent/CY1105975T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones orales para el tratamiento de humanos obesos y no diabéticos. Las composiciones farmacéuticas orales que comprenden una cantidad efectiva de un compuesto de tungsteno (VI), preferiblemente de una sal de tungstato, y más preferiblemente de tungstato sódico (Na2WO4), son útiles para combatir la obesidad/sobrepeso en humanos no diabéticos. Se ha determinado en ratas el efecto anti-obesidad del dihidrato de tungstato sódico en un modelo de obesidad inducida por la dieta denominado "dieta de cafetería". Estas ratas obesas son un buen modelo de humanos obesos y no diabéticos. El tratamiento profiláctico, terapéutico y/o cosmético que se deriva de esta invención es sorprendente y, sobre los tratamientos previamente propuestos en la técnica, conlleva ventajas tales como eficacia, ausencia de toxicidad y precio relativamente bajo. Por lo tanto, las composiciones orales de la presente invención son útiles para el tratamiento de la obesidad/sobrepeso en seres humanos no diabéticos.
ES200101200A 2001-05-16 2001-05-16 Composiciones orales para el tratamiento de humanos obesos y no diabeticos. Expired - Fee Related ES2187276B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200101200A ES2187276B1 (es) 2001-05-16 2001-05-16 Composiciones orales para el tratamiento de humanos obesos y no diabeticos.
PT02732763T PT1400246E (pt) 2001-05-16 2002-05-16 Composições orais para o tratamento de mamíferos obesos, não diabéticos, incluindo seres humanos
CA002447141A CA2447141A1 (en) 2001-05-16 2002-05-16 Oral compositions for the treatment of non-diabetic obese mammals, including humans
EP02732763A EP1400246B1 (en) 2001-05-16 2002-05-16 Oral compositions for the treatment of obese, non-diabetic mammals, including humans
BR0210975-1A BR0210975A (pt) 2001-05-16 2002-05-16 Composição oral para uso como um agente profilático, terapêutico e/ou cosmético para a obesidade/excesso de peso em mamìferos não diabéticos, inclusive em seres humanos e preparação de uma composição oral
US10/477,807 US7122209B2 (en) 2001-05-16 2002-05-16 Oral compositions for the treatment of non-diabetic obese mammals, including humans
ES02732763T ES2275873T3 (es) 2001-05-16 2002-05-16 Composiciones orales para el tratamiento de mamiferos obesos y no diabeticos incluyendo humanos.
DK02732763T DK1400246T3 (da) 2001-05-16 2002-05-16 Orale sammensætninger til behandling af adipöse, ikke-diabetiske pattedyr, indbefattet mennesker
PCT/ES2002/000231 WO2002098435A1 (es) 2001-05-16 2002-05-16 Composiciones orales para el tratamiento de mamíferos obesos y no diabéticos, incluyendo humanos
AT02732763T ATE344042T1 (de) 2001-05-16 2002-05-16 Orale zusammensetzungen zur behandlung von adipösen, nicht diabetischen säugetieren, einschliesslich menschen
DE60215812T DE60215812T2 (de) 2001-05-16 2002-05-16 Orale zusammensetzungen zur behandlung von adipösen, nicht diabetischen säugetieren, einschliesslich menschen
CY20071100138T CY1105975T1 (el) 2001-05-16 2007-01-31 Στοματικες συνθεσεις για την θepαπεια παχυσαρκων, μη διαβητικων θηλαστικων, πepιλαμβανομενων των ανθρωπων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200101200A ES2187276B1 (es) 2001-05-16 2001-05-16 Composiciones orales para el tratamiento de humanos obesos y no diabeticos.

Publications (2)

Publication Number Publication Date
ES2187276A1 true ES2187276A1 (es) 2003-05-16
ES2187276B1 ES2187276B1 (es) 2004-08-01

Family

ID=8497838

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200101200A Expired - Fee Related ES2187276B1 (es) 2001-05-16 2001-05-16 Composiciones orales para el tratamiento de humanos obesos y no diabeticos.
ES02732763T Expired - Lifetime ES2275873T3 (es) 2001-05-16 2002-05-16 Composiciones orales para el tratamiento de mamiferos obesos y no diabeticos incluyendo humanos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02732763T Expired - Lifetime ES2275873T3 (es) 2001-05-16 2002-05-16 Composiciones orales para el tratamiento de mamiferos obesos y no diabeticos incluyendo humanos.

Country Status (11)

Country Link
US (1) US7122209B2 (es)
EP (1) EP1400246B1 (es)
AT (1) ATE344042T1 (es)
BR (1) BR0210975A (es)
CA (1) CA2447141A1 (es)
CY (1) CY1105975T1 (es)
DE (1) DE60215812T2 (es)
DK (1) DK1400246T3 (es)
ES (2) ES2187276B1 (es)
PT (1) PT1400246E (es)
WO (1) WO2002098435A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551828A1 (es) * 2014-05-21 2015-11-23 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)
CN106715332A (zh) * 2014-07-21 2017-05-24 欧梭莱夫公司 用于治疗不孕症、促进雌性哺乳动物的正常繁殖和生育力及提高辅助生殖技术功效的钨盐

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206356A1 (en) * 2005-07-29 2008-08-28 Universidad De Barcelona Pharmaceutical Compositions for the Treatment of Neurodegenerative Disorders
DE102006062250A1 (de) * 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
CN100515428C (zh) * 2007-04-26 2009-07-22 暨南大学 钨酸锂在制药中的应用
ES2478790B1 (es) * 2013-01-22 2015-05-06 Oxolife, S. L. Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025928A (ja) * 1983-07-21 1985-02-08 Tanaka Seinosuke 薬剤
ES2108642A1 (es) * 1995-07-26 1997-12-16 Quimica Farm Bayer Sa Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4018513C1 (es) * 1989-12-20 1991-05-08 Karl Oexmann, Inh. Wolfgang Oexmann, 4650 Gelsenkirchen, De
US5192197A (en) * 1991-11-27 1993-03-09 Rockwell International Corporation Piezoelectric pump
CH689836A5 (fr) * 1994-01-14 1999-12-15 Westonbridge Int Ltd Micropompe.
US5611214A (en) * 1994-07-29 1997-03-18 Battelle Memorial Institute Microcomponent sheet architecture
US5595763A (en) * 1995-07-19 1997-01-21 Quimica Farmaceutica Bayer S.A. Tungsten (VI) compositions for the oral treatment of diabetes mellitus
US6148635A (en) * 1998-10-19 2000-11-21 The Board Of Trustees Of The University Of Illinois Active compressor vapor compression cycle integrated heat transfer device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025928A (ja) * 1983-07-21 1985-02-08 Tanaka Seinosuke 薬剤
ES2108642A1 (es) * 1995-07-26 1997-12-16 Quimica Farm Bayer Sa Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. MATSUMOTO, "Vanadate, Molybdate and Tungstate for Orthomolecular Medicine". Medical Hypotheses, 1994, Vol. 43, pßginas 177-182. Pßgina 179, tabla 1. *
J.D. FOSTER et al., "Tungstate: a Potent Inhibitor of multifunctional Glucose-6-Phosphatase". Archiv. Biochem. Biophys., 1998, Vol. 354, Nö 1, páginas 125-132. *
World Patents Index [en línea]. Londres (Reino Unido): Derwent Publications, Ltd. [recuperado el 03.07.2002]. Recuperado de: EPODOC, EPO. DW 198512, Nö de acceso 1985-071661 & JP 60025928 A (S. TANAKA) 08.02.1985 (resumen) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551828A1 (es) * 2014-05-21 2015-11-23 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)
CN106715332A (zh) * 2014-07-21 2017-05-24 欧梭莱夫公司 用于治疗不孕症、促进雌性哺乳动物的正常繁殖和生育力及提高辅助生殖技术功效的钨盐
CN106715332B (zh) * 2014-07-21 2019-01-29 欧梭莱夫公司 用于治疗不孕症、促进雌性哺乳动物的正常繁殖和生育力及提高辅助生殖技术功效的钨盐

Also Published As

Publication number Publication date
CA2447141A1 (en) 2002-12-12
PT1400246E (pt) 2007-02-28
BR0210975A (pt) 2004-10-05
ATE344042T1 (de) 2006-11-15
CY1105975T1 (el) 2011-04-06
DE60215812D1 (de) 2006-12-14
US7122209B2 (en) 2006-10-17
EP1400246A1 (en) 2004-03-24
DK1400246T3 (da) 2007-03-05
ES2187276B1 (es) 2004-08-01
US20040131697A1 (en) 2004-07-08
EP1400246B1 (en) 2006-11-02
ES2275873T3 (es) 2007-06-16
DE60215812T2 (de) 2007-08-30
WO2002098435A1 (es) 2002-12-12

Similar Documents

Publication Publication Date Title
RU2004110726A (ru) Применение оксинтомодулина, способ и фармацевтическая композиция для профилактики или лечения избыточной массы тела, способ снижения массы тела
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
TNSN99132A1 (fr) Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause
MXPA04005376A (es) Composiciones farmaceuticas y sus usos.
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
MXPA04012998A (es) Modulares de receptores nucleares de hormonas esteroideas triciclicos.
MXPA04004966A (es) Nucleosidos de 3-beta-d-ribofuranoziltiazol(4,5-d(pirimidina y uso de los mismos.
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
GB0102672D0 (en) Compounds
AU2003222841A1 (en) Phenethanolamine derivatives
WO2004029031A3 (en) Therapeutic piperazine compounds
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
SG156524A1 (en) New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
MXPA04003087A (es) Derivados de cromano como ligados de 5-hidroxitriptamina-6.
WO2002058692A3 (fr) Composition halogenee de hypohalites avec n-chloramine taurine, procede de preparation et ses utilisations
JP2979446B2 (ja) 口腔用組成物
ES2187276A1 (es) Composiciones orales para el tratamiento de humanos obesos y no diabeticos.
WO2002022111A3 (de) Kombination von liponsäure und konjuensäuren zur behandlung diabetischer störungen
WO2002070464A3 (en) Hydrazones and their therapeutic use
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
JP3031004B2 (ja) 口腔用組成物
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
BR0102211A (pt) Composição farmacêutica para o tratamento da obesidade ou para facilitar ou promover a perda de peso
BR9811293A (pt) Composições para o tratamento da alopecia, do hirsutismo feminino ou da seborréia, ou uma composição para a prevenção da metástase óssea causada por câncer prostático, e, usos de um composto e de n-{1-metil-1-(4-metoxifenil)etil}-3-oxo-4-aza-5-alfa-and rost-1-eno-17-beta-c arboxamida

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030516

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2187276B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20110817